Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
IGFBP1 Double Nickase Plasmid (h): sc-400915-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IGFBP1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- IGFBP1 Double Nickase Plasmid (h) and IGFBP1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting IGFBP1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IGFBP1 Antibody (H-5): sc-55474
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGFBP1 Double Nickase Plasmid (h) | sc-400915-NIC | 20 µg | $410.00 | |||
IGFBP1 Double Nickase Plasmid (h2) | sc-400915-NIC-2 | 20 µg | $410.00 |
IGFBP1 encodes insulin-like growth factor binding protein 1, a secreted regulator that binds IGF-I and IGF-II to modulate their bioavailability, receptor engagement, and downstream signaling through PI3K–AKT and MAPK pathways. IGFBP1 expression is strongly influenced by metabolic and hormonal cues, including insulin, glucocorticoids, and nutrient status, linking it to hepatic glucose homeostasis and systemic energy balance. By buffering IGF activity, IGFBP1 can shape cell proliferation, survival, and differentiation programs in endocrine and paracrine contexts. Altered IGFBP1 levels have been associated with metabolic dysregulation and with changes in IGF axis signaling observed across diverse pathophysiological states, supporting its utility as a mechanistic node in studies of growth-factor signaling and metabolism.
IGFBP1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the IGFBP1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within IGFBP1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt IGFBP1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of IGFBP1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.